Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors

[Image: see text] In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical development for the treatment of Alzheimer’s disease (AD). However, the alignment of drug-like properties and selectivity remains a major challenge. Herein, we describe the discovery of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodney, Michael A., Beck, Elizabeth M., Butler, Christopher R., Barreiro, Gabriela, Johnson, Eric F., Riddell, David, Parris, Kevin, Nolan, Charles E., Fan, Ying, Atchison, Kevin, Gonzales, Cathleen, Robshaw, Ashley E., Doran, Shawn D., Bundesmann, Mark W., Buzon, Leanne, Dutra, Jason, Henegar, Kevin, LaChapelle, Erik, Hou, Xinjun, Rogers, Bruce N., Pandit, Jayvardhan, Lira, Ricardo, Martinez-Alsina, Luis, Mikochik, Peter, Murray, John C., Ogilvie, Kevin, Price, Loren, Sakya, Subas M., Yu, Aijia, Zhang, Yong, O’Neill, Brian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415909/
https://www.ncbi.nlm.nih.gov/pubmed/25781223
http://dx.doi.org/10.1021/acs.jmedchem.5b00191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415909/
https://www.ncbi.nlm.nih.gov/pubmed/25781223
http://dx.doi.org/10.1021/acs.jmedchem.5b00191

Ejemplares similares